[DTIC in the therapy of solid tumours (author's transl)].
From 1975 to 1977 42 patients with advanced solid tumours were treated with imidazole-carboxamide (DTIC). It was applied in 18 cases as monotherapy: in the remaining patients it was administered in combination with other cytostatic agents. Tumour remission was recorded in 4/22 patients with melanoma, 2/2 with Kaposi sarcoma and 2/7 with soft tissue sarcoma. No change in tumour behaviour was recorded in 6/22 melanomas, 2/7 soft tissue sarcomas, 1/7 head and neck tumours and 1/1 thymoma. Side effects of DTIC monotherapy were comparably low. The optimum dosage and frequency of DTIC therapy have not yet been established. Combinations with other cytostatic agents are still being tested.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy; D012514:Sarcoma, Kaposi / Q000188:drug therapy; D012983:Soft Tissue Neoplasms / Q000188:drug therapy; D013945:Thymoma / Q000188:drug therapy; D013953:Thymus Neoplasms / Q000188:drug therapy; D014226:Triazenes / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014226:Triazenes; D003606:Dacarbazine
DTIC in der Therapie solider Tumoren.